Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
Former NBA player Michael Carter-Williams is hoping to get a WNBA franchise in Boston whether it's through expansion or being ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
According to Benzinga Pro, Carlyle Group's peer group average for short interest as a percentage of float is 3.15%, which means the company has more short interest than most of its peers. Did you know ...
Sedgwick, a provider of claims management, loss adjusting and technology-enabled business solutions, has agreed to acquire Thoma Bravo -based Bottomline’s legal spend management division. No financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results